The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases.

Wannee KantasiripitakBram VerstocktDahham AlsoudTriana LobatónDebby ThomasAnn GilsSéverine VermeireMarc FerranteErwin Dreesen

Published in: British journal of clinical pharmacology (2021)

Elderly patients attained infliximab exposure and endoscopic remission similarly to nonelderly patients. Therefore, the same infliximab trough concentration target can be used in therapeutic drug monitoring. The hazards of severe adverse events and malignancy increased with age, but not with infliximab exposure.

Keyphrases

ulcerative colitis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
drug induced